A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Phase 2
Terminated
- Conditions
- Stroke
- Registration Number
- NCT00073476
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Males & females age 40-90 years
Enrolled in study within 6 hours of onset of stroke symptoms
Willing to sign informed consent form
No significant disabilities prior to stroke
Exclusion Criteria
Treatment with t-PA (tissue plasminogen activator)
Premorbid modified rankin scale score of 2 or more
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method No or minimal neurological deficit at last visit Marked neurological improvement at last visit
- Secondary Outcome Measures
Name Time Method Modified Rankin scale at last visit Mortality Safety assessments
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇪🇸Zaragoza, Spain